Transforming Eye Care: Oculis Advances Precision Medicine for Dry Eye Disease Oculis is advancing it’s precision medicine approach for treating dry eye disease with plans for a phase 3 study of its anti-TNFα eye drop, licaminlimab (OCS-02). Recent phase 2b results showed promising treatment effects, especially in patients with a specific TNFR1-related genotype. This innovative approach could revolutionize ophthalmology by tailoring treatments to individual genetic profiles. What are your thoughts on this advancement? Oculis CEO Riad SHERIF, M.D., said in a statement that the precision medicine approach could “transform the way we develop drugs and treat patients in ophthalmology.” Read more in the article in the comment below. #Biotech #PrecisionMedicine #Ophthalmology #ClinicalTrials #DryEyeDisease #Innovation #Healthcare
Prevail InfoWorks’ Post
More Relevant Posts
-
Glaucoma, often called the "silent thief of sight," presents a significant challenge in ophthalmology. Despite progress in treatment, several unmet needs persist, hindering effective management and vision preservation. Through early detection, personalized approaches, exploration of new therapeutic targets, surgical advancements, patient education, and collaborative care models, we can address these challenges and enhance outcomes in glaucoma management. It's crucial to unite efforts and innovate solutions to protect the precious gift of sight for millions affected by this insidious disease. Glaucoma often goes undetected in many patients due to various factors. According to DelveInsight Business Research LLP's estimates, of the 16 million prevalent cases in 2022 across the 7MM, only 7 million received a formal diagnosis. Prominent players such as NICOX OPHTHALMICS INC, Sun Pharma Advanced Research Company Ltd., Visiox Pharmaceuticals, and others are working proactively in the Glaucoma market. Explore more about the treatment options in the Glaucoma market @ https://lnkd.in/gQh2n8x4 #glaucoma #glaucomamarket #glaucomatreatmentmarket #glaucomatreatment #treatmentoptions #ophthalmology
Addressing Unmet Needs in Glaucoma Treatment
https://www.delveinsight.com/blog
To view or add a comment, sign in
-
Opthea announced the publication of a scientific review in the peer-reviewed journal Ophthalmology and Therapy. The publication, Vascular Endothelial Growth Factor (VEGF) C and D Signaling Pathways as Potential Targets for the Treatment of neovascular (wet) AMD supports the scientific rationale for sozinibercept (OPT-302) as a potential treatment for wet AMD: https://bit.ly/3Lhxwig
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD - Eyewire
eyewire.news
To view or add a comment, sign in
-
Patients treated with dihydropyridine calcium channel blockers are more likely to develop primary open angle glaucoma (POAG), according to research published in Ophthalmology Glaucoma (American Academy of Ophthalmology, American Glaucoma Society). Read more: https://brnw.ch/21wLkbx #DihydropyridineCalciumChannelBlockers #PrimaryOpenAngleGlaucoma #Glaucoma #Ophthalmology #EyeHealth #EyeCare #Ophthalmologist
Dihydropyridine Calcium Channel Blockers Raise Glaucoma Risk
https://www.ophthalmologyadvisor.com
To view or add a comment, sign in
-
Innovative breakthroughs in the field of ophthalmology are definitely revolutionizing the treatment of the retinal diseases like macular degeneration, retinitis, pigmentosa and gyrate atrophy. https://lnkd.in/gKYEPzhQ
Revolutionizing Retinal Disease Treatment: New Breakthroughs Offer Hope for Sufferers
https://medriva.com
To view or add a comment, sign in
-
Ophthalmology is a growing area in clinical development, propelled by recent advancements and heightened attention to developing retinal disease solutions. Given the complexities in conducting ophthalmology trials, success often requires strong collaboration between the CRO and Sponsor. Medpace is a trusted ally, with deep experience in retinal diseases and strong team collaboration to help build long-term relationships with Sponsors. Dive deeper into the emerging trends of #ophthalmology in our latest blog from Zaiba Malik, M.D. and Tracy Huiet: https://lnkd.in/g857sdp4
[Blog] Emerging Trends in Ophthalmology – A Look into the Clinical Development Landscape
medpace.com
To view or add a comment, sign in
-
Ophthalmology Is Growing Strong One trend you can expect to see this year is growth. The ophthalmology therapeutics industry expects to expand substantially over the next several years. Unfortunately, one of the reasons for this growth is a high incidence of eye diseases, including glaucoma and macular degeneration. #ophthalmology #ophthalmic #medical #medicalequipmentsupplier
To view or add a comment, sign in
-
Test your knowledge with a new HCPLive Clinician Quiz! In this quiz, we ask questions based on clinical assessment recommendations for patients with inherited retinal diseases from 2022 American Academy of Ophthalmology guidelines. https://lnkd.in/ew89WHrR #ophthalmology
Clinician Quiz: AAO Guidelines for Inherited Retinal Degenerations
hcplive.com
To view or add a comment, sign in
-
🌟 Empowering Macular Degeneration Treatment: Subanalysis of TENAYA and LUCERNE Study Reveals Positive Outcomes in Asian and Japanese Populations! 🌟 I'm thrilled to share a significant stride in the field of ophthalmology — the outcomes of subanalyses focusing on Asian and Japanese patients within a landmark international study investigating the efficacy, durability, and safety of faricimab in neovascular age-related macular degeneration (nAMD). 👁️ Subanalysis 1: "Faricimab in Asian Patients with nAMD: A Closer Look" In this subanalysis of the TENAYA and LUCERNE trials by Kanji Takahashi et al., researchers delved into the response of patients from Asian countries. The findings unveiled a story of promise and progress. Patients treated with faricimab demonstrated a significant mean BCVA change of 7.1 letters, akin to those receiving aflibercept. Notably, an impressive 59.6% of Asian patients achieved a 16-week dosing interval, showcasing the potential for extended treatment intervals while maintaining efficacy. The safety profile of faricimab continued to hold strong, fostering confidence in its use for nAMD management. 👁️ Subanalysis 2: "Faricimab in Japanese Patients with nAMD: A Step Forward" Ryusaburo Mori et al. conducted a subanalysis within the Japan subgroup of the broader TENAYA trial. The results aligned harmoniously with the global study, further bolstering the case for faricimab's efficacy and safety. With a 7.1-letter BCVA improvement, patients on a 16-week dosing interval stood at 66.1%. This outcome echoes convenience and potential benefit for Japanese patients, mirroring the broader international context. These subanalyses underscore the versatility and efficacy of faricimab across diverse patient populations, while also highlighting the significance of tailored treatment strategies. The unity in results between these focused analyses and the larger international trials solidifies faricimab's standing as a potential transformative therapy for nAMD. For comprehensive insights, access the full papers here: https://lnkd.in/gxGcCMNr https://lnkd.in/g7pHR_r8 #OphthalmicAdvancements #Faricimab #nAMD #TailoredTreatment #BetterVisionAhead
Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials - Graefe's Archive for Clinical and Experimental Ophthalmology
link.springer.com
To view or add a comment, sign in
-
Experienced Senior Leader in Sales | Key Account Acquisition, Sales Strategy | Healthcare & Life Science Expertise | Multimillion-Dollar Deals | Trainer & Mentor
Exciting developments in ophthalmology! It's fascinating to see how companies are pushing boundaries to improve eye health. Check it out and share your thoughts! 👁️💡 #Ophthalmology #Innovation #HealthTech"
What are some of the new innovations in ophthalmology? Check out this article (via GeneOnline) that features companies doing work in macular degeneration, diabetic retinopathy and retinal diseases. https://lnkd.in/g-thC4J9 ______________________________ #ophthalmology #clinicaltrials #lifesciences
Biotech Showcase 2024: Innovation in the Ophthalmology Sector
geneonline.com
To view or add a comment, sign in
Link to the article: https://www.fiercebiotech.com/biotech/oculis-sees-promise-dry-eye-disease-subgroup-plans-phase-3